Olov Andersson

Olov Andersson

Auto-generated profile, based on publicly available information

Olov Andersson

Uppsala University 1 Department of Medical Cell Biology BMC, Husargatan 3, 75123 Uppsala

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Cell Metabolism
Verified
Journal Article
Closed access
OAOlov Andersson
Olov Andersson
BABruce A. Adams
Bruce A. Adams
DYDaniel Yoo
Daniel Yoo
GEGregory C. Ellis
Gregory C. Ellis
PGPhilipp Gut
Philipp Gut
DSDidier Y.R. Stainier
Didier Y.R. Stainier

9 October 2023 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
JSJoel Spratt
Joel Spratt
JDJosé M. Dias
José M. Dias
CKChristina Kolonelou
Christina Kolonelou
GKGeorges Kiriako
Georges Kiriako
EEEnya Engström
Enya Engström
ATAna I. Teixeira
Ana I. Teixeira
Insulin binds the insulin receptor (IR) and regulates anabolic processes in target tissues. Impaired IR signalling is associated with multiple diseases, including diabetes, cancer and neurodegenerative disorders. IRs have been reported to form nanoclusters at the cell membrane in several cell types, even in the absence of insulin binding. Here we exploit the nanoscale spatial organization of the IR to achieve controlled multivalent receptor activation. To control insulin nanoscale spatial organization and valency, we developed rod-like insulin–DNA origami nanostructures carrying different numbers of insulin molecules with defined spacings. Increasing the insulin valency per nanostructure markedly extended the residence time of insulin–DNA origami nanostructures at the receptors. Both insulin valency and spacing affected the levels of IR activation in adipocytes. Moreover, the multivalent insulin design associated with the highest levels of IR activation also induced insulin-mediated transcriptional responses more effectively than the corresponding monovalent insulin nanostructures. In an in vivo zebrafish model of diabetes, treatment with multivalent—but not monovalent—insulin nanostructures elicited a reduction in glucose levels. Our results show that the control of insulin multivalency and spatial organization with nanoscale precision modulates the IR responses, independent of the insulin concentration. Therefore, we propose insulin nanoscale organization as a design parameter in developing new insulin therapies.

11 August 2016 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JLJing Lu
Jing Lu
KLKa‐Cheuk Liu
Ka‐Cheuk Liu
NSNadja Schulz
Nadja Schulz
CKChristos Karampelias
Christos Karampelias
JCJérémie Charbord
Jérémie Charbord
OAOlov Andersson
Olov Andersson
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

6 October 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
KLKa-Cheuk Liu
Ka-Cheuk Liu
GLGunter Leuckx
Gunter Leuckx
DSDaisuke Sakano
Daisuke Sakano
PSPhilip A. Seymour
Philip A. Seymour
CMCharlotte L. Mattsson
Charlotte L. Mattsson
OAOlov Andersson
Olov Andersson
Inhibition of notch signalling is known to induce differentiation of endocrine cells in zebrafish and mouse. After performing an unbiased in vivo screen of ∼2200 small molecules in zebrafish we identified an inhibitor of Cdk5 (roscovitine), which potentiated formation of β-cells along the intra-pancreatic duct during concurrent inhibition of notch signalling. We confirmed and characterized the effect with a more selective Cdk5 inhibitor, (R)-DRF053, which specifically increased the number of duct-derived β-cells without affecting their proliferation. By duct-specific overexpression of the endogenous Cdk5 inhibitors Cdk5rap1 or Cdkal1 (which previously have been linked to diabetes in GWAS), as well as deleting cdk5, we validated the role of chemical Cdk5 inhibition in β-cell differentiation by genetic means. Moreover, the cdk5 mutant zebrafish displayed an increased number of β-cells independently of inhibition of notch signalling, in both the basal state and during β-cell regeneration. Importantly, the effect of Cdk5 inhibition to promote β-cell formation was conserved in mouse embryonic pancreatic explants, adult mice with pancreatic ductal ligation injury and human iPS cells. Thus, we have revealed a previously unknown role of Cdk5 as an endogenous suppressor of β-cell differentiation, and thereby further highlighted its importance in diabetes.

20 May 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JCJérémie Charbord
Jérémie Charbord
LRLipeng Ren
Lipeng Ren
RSRohit B. Sharma
Rohit B. Sharma
AJAnna Johansson
Anna Johansson
RÅRasmus Ågren
Rasmus Ågren
OAOlov Andersson
Olov Andersson

7 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKChristos Karampelias
Christos Karampelias
HRHabib Rezanejad
Habib Rezanejad
MRMandy Rosko
Mandy Rosko
LDLikun Duan
Likun Duan
JLJing Lu
Jing Lu
OAOlov Andersson
Olov Andersson
Diabetes can be caused by an insufficiency in β-cell mass. Here, we performed a genetic screen in a zebrafish model of β-cell loss to identify pathways promoting β-cell regeneration. We found that both folate receptor 1 (folr1) overexpression and treatment with folinic acid, stimulated β-cell differentiation in zebrafish. Treatment with folinic acid also stimulated β-cell differentiation in cultures of neonatal pig islets, showing that the effect could be translated to a mammalian system. In both zebrafish and neonatal pig islets, the increased β-cell differentiation originated from ductal cells. Mechanistically, comparative metabolomic analysis of zebrafish with/without β-cell ablation and with/without folinic acid treatment indicated β-cell regeneration could be attributed to changes in the pyrimidine, carnitine, and serine pathways. Overall, our results suggest evolutionarily conserved and previously unknown roles for folic acid and one-carbon metabolism in the generation of β-cells.